Detalhe da pesquisa
1.
Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages.
J Inherit Metab Dis
; 37(3): 341-52, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24492980
2.
Relapse in ocular tuberculosis: relapse rate, risk factors and clinical management in a non-endemic country.
Br J Ophthalmol
; 2024 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38609164
3.
Clinical Features and Predictors of Treatment Outcome in Patients with Ocular Tuberculosis from the Netherlands and Indonesia: The OculaR TB in Low versus High Endemic Countries (ORTEC) Study.
Ocul Immunol Inflamm
; : 1-12, 2024 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38820475
4.
The Humira in Ocular Inflammations Taper (HOT) Study.
Am J Ophthalmol
; 258: 87-98, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37734639
5.
The immune response in tubercular uveitis and its implications for treatment: From anti-tubercular treatment to host-directed therapies.
Prog Retin Eye Res
; 95: 101189, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37236420
6.
Long-Term Follow-Up of Patients with Scleritis After Rituximab Treatment Including B Cell Monitoring.
Ocul Immunol Inflamm
; : 1-6, 2023 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37437135
7.
COVID-19 Incidence and Disease Course Among Patients at an Allergy Department.
Ther Adv Allergy Rhinol
; 14: 27534030231172391, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37207194
8.
Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy.
Biochim Biophys Acta
; 1812(1): 70-6, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20851180
9.
Prevalence of symptoms in female Fabry disease patients: a case-control survey.
J Inherit Metab Dis
; 35(5): 891-8, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22431073
10.
Long-Term Follow-up of Patients With Uveitis Treated With Adalimumab: Response Rates and Reasons for Discontinuation of Therapy.
Am J Ophthalmol
; 240: 194-204, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35314190
11.
Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies.
J Inherit Metab Dis
; 34(3): 605-19, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21445610
12.
Elevated globotriaosylsphingosine is a hallmark of Fabry disease.
Proc Natl Acad Sci U S A
; 105(8): 2812-7, 2008 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-18287059
13.
The value of anti-neutrophil cytoplasmic antibodies (ANCA) testing for the diagnosis of ANCA-associated vasculitis, a systematic review and meta-analysis.
Autoimmun Rev
; 20(1): 102716, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33197574
14.
Inflammatory bowel disease in primary immunodeficiency disorders is a heterogeneous clinical entity requiring an individualized treatment strategy: A systematic review.
Autoimmun Rev
; 20(8): 102872, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34118459
15.
Assessment of immediate and non-immediate hypersensitivity contrast reactions by skin tests and provocation tests: A review.
Int J Immunopathol Pharmacol
; 35: 20587384211015061, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34053316
16.
Characteristics of COVID-19 infection and antibody formation in patients known at a tertiary immunology department.
J Transl Autoimmun
; 4: 100084, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33532723
17.
The value of estimated GFR in comparison to measured GFR for the assessment of renal function in adult patients with Fabry disease.
Nephrol Dial Transplant
; 25(8): 2549-56, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20215390
18.
Cost-effectiveness of enzyme replacement therapy for Fabry disease.
Orphanet J Rare Dis
; 8: 29, 2013 Feb 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-23421808
19.
Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain.
Orphanet J Rare Dis
; 8: 47, 2013 Mar 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-23531228
20.
Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome.
PLoS One
; 7(10): e47805, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-23094092